| Date | Title | | | 05/09/12 | MannKind Corporation Reports 2012 First Quarter Financial Results|
- Conference Call to Begin Today at 5:00 PM EDT -
VALENCIA, Calif.--(BUSINESS WIRE)--May. 9, 2012--
MannKind Corporation (Nasdaq: MNKD) today reported financial
results for the first quarter ended March 31, 2012.
For the first quarter of 2012, total operating expenses were $33.9
million, compared to $38.1 million for the first quarter of 2011, a
decrease of $4.1 million. Research and development (R&D) expenses were
... |
|  | | 05/08/12 | MannKind to Present at Bank of America Merrill Lynch 2012 Health Care Conference| VALENCIA, Calif.--(BUSINESS WIRE)--May. 8, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Bank of America Merrill Lynch 2012 Health
Care Conference on Tuesday, May 15, 2012 at 10:40 am Pacific Daylight
Time at the Encore at the Wynn in Las Vegas, Nevada.
Interested parties can access a link to the live webcast of... |
| | | 05/02/12 | MannKind Corporation to Hold 2012 First Quarter Financial Results Conference Call on May 9, 2012| VALENCIA, Calif.--(BUSINESS WIRE)--May. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) will release its 2012 first
quarter financial results on Wednesday, May 9, 2012 and its management
will host a conference call to discuss the first quarter financial
results and other Company developments at 5:00 PM (Eastern Time) on May
9, 2012.
Presenting from the Company will be its Chairman and Chief Executive
Officer, Alfred Mann, President and C... |
| | | 04/30/12 | Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases| SALT LAKE CITY & VALENCIA, Calif.--(BUSINESS WIRE)--Apr. 30, 2012--
Tolero Pharmaceuticals, a biopharmaceutical company focused on the
discovery and development of novel therapeutics to treat cancer and
other serious human diseases, and MannKind Corporation (Nasdaq: MNKD),
focused on discovering, developing and commercializing therapeutic
products for diabetes and cancer, today announced a license agreement
granting Tolero exclusive worldwide rig... |
| | | 04/10/12 | MannKind to Present at Imperial Capital 2012 Healthcare Investor Forum| VALENCIA, Calif.--(BUSINESS WIRE)--Apr. 10, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Imperial Capital 2012 Healthcare Investor
Forum on Tuesday, April 17, 2012 at 9:00 am Eastern Time at the New York
Palace in New York.
Interested parties can access a link to the live webcast of the
presentations fro... |
| | | 02/29/12 | MannKind to Present at Cowen and Company 32nd Annual Health Care Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 29, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Cowen and Company 32nd Annual Health Care
Conference on March 7, 2012 at 10:40am Eastern at the Boston Marriott
Copley Place in Boston, Massachusetts.
Interested parties can access a link to the live webcast of the
p... |
| | | 02/22/12 | MannKind Corporation Reports 2011 Fourth Quarter and Full Year Financial Results|
- Conference Call to Begin Today at 5:00 PM EST -
VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 22, 2012--
MannKind Corporation (Nasdaq: MNKD) today reported financial
results for the fourth quarter and year ended December 31, 2011.
For the fourth quarter of 2011, total operating expenses were $30.6
million, compared to $32.1 million for the fourth quarter of 2010, a
decrease of $1.5 million. Research and development (R&D) expenses were... |
| | | 02/15/12 | MannKind Corporation to Hold 2011 Fourth Quarter and Full Year Financial Results Conference Call on February 22, 2012| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 15, 2012--
MannKind Corporation (Nasdaq: MNKD) will release its 2011 fourth
quarter and full year financial results on Wednesday, February 22, 2012
and its management will host a conference call to discuss the fourth
quarter and full year financial results and other Company developments
at 5:00 PM (Eastern Time) on February 22, 2012.
Presenting from the Company will be its Chairman and Chief Executive
... |
| | | 02/08/12 | MannKind Announces Exercise In Full of Over-Allotment Option and Completion of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 8, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced the
completion of an underwritten public offering of 35,937,500 units,
including 4,687,500 units sold pursuant to the full exercise of an
over-allotment option previously granted to the underwriters (with each
unit consisting of one share of its common stock and a warrant to
purchase 0.6 of a share of its common stock). All of the securities were
... |
| | | 02/07/12 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 7, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at upcoming conferences.
The 14th Annual BioCEO Investor Conference on February 14,
2012 at 2:00 p.m. ET at the Waldorf-Astoria in New York, New York
The Leerink Swann 2012 Global Healthcare Conference... |
| | | 02/02/12 | MannKind Receives Commitment from The Mann Group to Acquire 31,250,000 Shares of Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it has
entered into a purchase agreement with The Mann Group LLC, an entity
controlled by MannKind’s chief executive officer and principal
stockholder, Alfred E. Mann, for the sale of shares of its common stock
to The Mann Group. The Mann Group has committed to purchase 31,250,000
restricted shares of MannKind’s common stock, the same number of ... |
| | | 02/02/12 | MannKind Announces Pricing of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced the pricing
of an underwritten public offering of 31,250,000 units, with each unit
consisting of one share of its common stock and a warrant to purchase
0.6 of a share of its common stock. The shares of common stock and the
warrants are being offered at a combined price to the public of $2.40
per unit. The gross proceeds to MannKind from this offerin... |
| | | 01/31/12 | MannKind Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 31, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it
intends to offer and sell, subject to market and other conditions, $50
million worth of units in an underwritten public offering, with each
unit consisting of one share of MannKind’s common stock and a warrant to
purchase 0.6 of a share of MannKind’s common stock. MannKind also
intends to grant to the underwriters of the offering an option t... |
| | | 01/05/12 | MannKind to Present at 30th Annual J.P. Morgan Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 5, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at the 30th Annual J.P. Morgan
Healthcare Conference on Thursday, January 12, 2012 at 8:00 am (PT) at
the Westin St. Francis Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the
... |
| |
|
